STaRT emulates nature, in that it utilizes mimetics for the body’s wound-healing signals to program mesenchymal stem/stromal cells [MSC] for specific immunomodulatory action. MSCs primed by STaRT are imbued with greater migratory capabilities, enabling them to “home” to sites of immune dysfunction following simple IV administration. Primed MSCs exert their multi-pronged mechanism of action to reboot an appropriate immune response via paracrine effects and cell-to-cell contact.
SAFETY: Tested in >300 subjects in pre-clinical studies with no major adverse events
UNIFORMITY: Priming converts heterogenous naive MSC cell populations to a homogeneous phenotype, yielding a more potent cell dose with consistent results
HOMING: Cells have greater migration capabilities and improved biodistribution versus naive MSCs
MECHANISM OF ACTION: Primed MSCs broadly target innate and adaptive immune mechanisms with a variety of paracrine and cell contact effects
SIMPLE MANUFACTURING: The priming step is applied towards the end of already well-established cell therapy production processes to efficiently create low-dose, off-the-shelf therapies
APPLICABILITY: Consistent results observed with allogeneic (healthy donor) or autologous (patient-specific) cells, and MSCs from humans, dogs, horses, mice, and prospectively, any mammalian MSC given sufficient TLR expression.